Johnson & Johnson has successfully acquired Momenta Pharmaceuticals. Momenta Pharmaceuticals is a company that discovers and develops therapies for immune-mediated diseases.
"We're delighted to welcome Momenta's talented team to the Janssen Pharmaceutical Companies of Johnson & Johnson and to begin our work together to further advance patient care in autoantibody-driven diseases," said Jennifer Taubert, executive vice president and worldwide chair of pharmaceuticals, Johnson & Johnson. "We anticipate multiple launches, many of which would be first-in-class indications in rare diseases and areas of significant unmet need."
